Eli Lilly's stock is soaring while Novo Nordisk is sinking. Why it makes sense to stick with the market winner, despite its rising valuation.
Get this delivered to your inbox, and more info about our products and services.
Lilly shares rose more than 4% Monday, while rival Novo Nordisk tanked.
Club holding Lilly stock slumped 1% Tuesday while Novo Nordisk shares jumped nearly 9%.
The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its…
Novo Nordisk is losing market share despite its having a "comprehensive portfolio" compared to peers, the firm said.
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures…
